When was Step Pharma founded?

Step Pharma was founded in 2014 and raised its 1st funding round within a year of its incorporation.

Where is Step Pharma located?

Step Pharma is headquartered in Saint-Genis-Pouilly, France.

Which legal entities is Step Pharma associated with?

Step Pharma is associated with Step Pharma.

How many employees does Step Pharma have?

As of May 31, 2026, the latest employee count at Step Pharma is 15.

Is Step Pharma a funded company?

Step Pharma is a funded company, having raised a total of $95.7M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 2014.

When was the latest funding round of Step Pharma?

Step Pharma's latest funding was a $***** Grant (prize money) round on Feb 19, 2026, with participation from 1 investor.

What is the annual revenue of Step Pharma?

Annual revenue of Step Pharma is less than €1M as on Dec 31, 2020

Where does Step Pharma rank among its competitors?

Step Pharma ranks 182nd amongst 2426 active competitors, of which 844 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Karyopharm, which secured $30M in Mar, 2026.

Who are the top competitors of Step Pharma?

Step Pharma's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Among them, Karyopharm secured the most recent funding round in March, 2026.

Step Pharma - 2026 Company Profile, Team, Funding, Competitors & Financials

Step Pharma is a series C company based in Saint-Genis-Pouilly (France), founded in 2014 by Geoffroy De Ribains. It operates as a Developer of targeted oncology therapies inhibiting CTPS1 for cancer treatment. Step Pharma has raised $95.7M in funding from investors like Sunstone, Idinvest Partners and Kurma Partners. The company has 2426 active competitors, including 844 funded and 600 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines.

Company Details

Developer of targeted oncology therapies inhibiting CTPS1 for cancer treatment. The company focuses on creating selective, orally bioavailable drugs for blood cancers and solid tumors. Their lead asset is in clinical development for lymphoma, ovarian cancer, and essential thrombocythaemia. Future development may include treatment regimens for solid tumours.

Website: step-ph.com
Email ID: *****@step-ph.com

Key Metrics

Founded Year

2014

Location

Saint-Genis-Pouilly, France

Stage

Series C

Total Funding

$95.7M in 5 rounds

Latest Funding Round

Grant (prize money), Feb 19, 2026, $*****

Investors

Sunstone & 10 more

Ranked

182^nd among 2426 active competitors

Annual Revenue

€0 - €1M as on Dec 31, 2020

Employee Count

15 as on May 31, 2026

Similar Companies

Amphista Therapeutics & 24 more

View Step Pharma's full profile

Step Pharma is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Step Pharma CIN: 802795906 , France, Active	May 16, 2014	€0 - €1M (As on Dec 31, 2020)	-	-

Step Pharma has raised a total funding of $95.7M over 5 rounds. Its first funding round was on Jul 2014. Its latest funding round was a Grant (prize money) round on Feb 19, 2026 for $*****. 1 investor participated in its latest round. Step Pharma has 11 institutional investors.

Here is the list of recent funding rounds of Step Pharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 19, 2026	2652166	Grant (prize money)	2618116	9210325	7593085	5836949
Oct 15, 2025	5824490	Series C	4905410	8529060	1685988	Pontifax & 5 more
Mar 24, 2021	1301983	Series B	3480969	1834198	Hadean Ventures & 1 more	Kurma Partners & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Step Pharma's funding rounds and investors

The founders of Step Pharma is Geoffroy De Ribains. Andy Parker is the CEO of Step Pharma.

Here are the details of Step Pharma's key team members:

Geoffroy De Ribains: Former Co-Founder of Step Pharma and founder of 1 other company.

View details of Step Pharma's Founder profiles and Board Members

Step Pharma's employee count trend

Step Pharma has 15 employees as of May 26. Here is Step Pharma's employee count trend over the years:

Uncover Step Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Step Pharma include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Here is the list of Top 10 competitors of Step Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
3rd	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
5th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Karyopharm 2008, Natick (United States), Public	Developer of small molecule drugs for the treatment of cancer and inflammatory disease	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	CTI Life Sciences Fund, Advanced Biotechnologies Venture Fund ... & 16 others	71/100
182nd	Step Pharma 2014, Saint-Genis-Pouilly (France), Series C	Developer of targeted oncology therapies inhibiting CTPS1 for cancer treatment	$95.7M	Sunstone, Pontifax & 9 others	58/100